StockData
Helus Pharma Inc. logo

Helus Pharma Inc. (HELP) stock

HELPNasdaqPharmaceutical PreparationsFiscal year ends March 31
Financials through fiscal 2026, year ended Mar 31, 2026Last filing: 40-F on Jun 29, 2026Score 0/30
$8.86−0.53 (-5.64%)

Close on Nov 12, 2026Market cap $457.46MP/E –Yield –

Earnings

Helus Pharma's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.

Next report
–
Not yet scheduled
Revenue
–
EPS
–
Latest guidance
None
No outlook given in releases

Quarterly results

Revenue and earnings per share from each of Helus Pharma's earnings releases, newest first

QuarterReportedRevenueYoYEPSSource
Q4 FY2022ended Mar 31, 2022Jun 22, 2022before the open–––Release

Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.

Guidance

Helus Pharma has not given guidance in its releases

Many companies give their outlook only on the conference call or not at all. When Helus Pharma puts a forecast in an earnings release, it is listed here with the exact sentence.

Press releases

Releases Helus Pharma filed with the SEC as exhibits to Form 8-K or 6-K

  1. Item 1. Name and Address of Company
    6-K
  2. Helus Pharma to Participate in the Guggenheim Healthcare Innovation Conference
    6-K
  3. Helus Pharma Announces Co-Founders' Transition from Executive
    6-K
  4. Helus Pharma Highlights Clinical Program Advancements at Investor Presentation Held on October 21, 2026
    6-K
  5. Helus Pharma Appoints Dr. Suresh Durgam to Board of Directors
    6-K
  6. Helus Pharma to Host Investor Presentation on October 21, 2026
    6-K
  7. 6-K exhibit EX-99.1
    6-K
  8. Item 1. Name and Address of Company
    6-K
  9. Helus Pharma Announces Completion of Legal Name Change
    6-K
  10. Helus Pharma Announces Results of Annual and Special Meeting of Shareholders and Effective Date for Legal Name Change
    6-K
  11. SECTION 11.3 OF NATIONAL INSTRUMENT 51-102
    6-K
  12. Helus Pharma to Participate at the TD Cowen 6th Annual Novel Mechanisms in Neuropsychiatry Summit
    6-K
  13. Helus Pharma Presents New Analyses on HLP003 in Major Depressive Disorder at Psych Congress 2026
    6-K
  14. Helus Pharma to Participate at the Morgan Stanley 24 th Annual Global Healthcare Conference in New York
    6-K
  15. Helus Pharma to Participate at the H.C. Wainwright 28th Annual Global Investment Conference in New York
    6-K

See a number that looks wrong?